INDUSTRY OVERVIEW
The Artificial Intelligence (AI) in Oncology is Growing at 26.50% and is expected to reach 4.7Billion by 2032. Below mentioned are some of the dynamics shaping the Artificial Intelligence (AI) in Oncology.Artificial Intelligence (AI) in Oncology Market Size in (USD Billion) CAGR Growth Rate 26.50%
| Study Period | 2020-2032 |
| Market Size (2024): | 1.1Billion |
| Market Size (2032): | 4.7Billion |
| CAGR (2024 - 2032): | 26.50% |
| Fastest Growing Region | Asia-Pacific |
| Dominating Region | North America |
www.www.htfmarketinsights.com
AI in Oncology utilizes artificial intelligence technologies to improve cancer diagnosis, treatment planning, and patient management. AI algorithms analyze medical images, genomic data, and clinical records to detect cancer early and recommend personalized therapies. It supports clinicians in making informed decisions and advancing precision oncology. This technology accelerates drug discovery and clinical trial design for better cancer outcomes.
Need More Details on Market Players and Competitors?
DOWNLOAD Sample Report
Regulatory Landscape
- Regulations require strict validation of AI algorithms for diagnosis, prognosis, and treatment planning. Data security and patient consent are critical, alongside clinical efficacy evidence.
Market Drivers:
The key drivers in the market include technological advancements, increasing demand by consumers for innovative products, and government-friendly policies. Our research company combines industry reports with expert interviews and market analysis tools to identify and quantify drivers such as these. We review the current trends and gather data from leading industry publications and market research firms to decipher exactly how these and other factors are encouraging or dampening market growth.
- Rising Cancer Cases
- Precision Medicine Demand
- AI Tech Improvements
- Healthcare Digitization
Market Restraints:
Some of the restraints to market growth may include regulatory challenges, high production costs, and disruptions in the supply chain. Our sources for these limitations include the regulation filings, industry surveys, and direct contributions from active participants within this marketplace. Tracking policy updates and economic reports further helps us to determine what kind of effect these factors have on the industry.
- Regulatory Complexity
- Data Security
- AI Transparency
- Adoption Barriers
Trends in the Market:
Among the trending ones are sustainability, digital transformation, and increasing importance of data analytics. Our research company is tracking these trends through the use of trend analysis tools, social media sentiment analysis, and industry benchmarking studies. Insights in emerging market preferences and technological advancements also come from surveys and focus groups.
- AI-assisted imaging
- Predictive oncology models
- AI drug discovery
- Patient monitoring platforms
Market Opportunities:
These include emerging markets, innovation in product development, and strategic partnerships. We identify these opportunities by performing market segmentation analysis, competitive landscape assessment, and investment trend evaluation. The data is collected based on industry reports, financial performance analysis for major players, and forecasting models for identifying future growth areas.
- Oncology Clinical Decision Support
- AI-powered Drug Pipelines
- Personalized Therapies
- Early Detection Tools
Check Out Prices
Get Price
Regulation Shaping the Healthcare Industry
The healthcare industry is significantly influenced by a complex framework of regulations designed to ensure patient safety, efficacy of treatments, and the overall quality of care. Key regulatory areas include drug approval processes, medical device standards, and healthcare data protection. These regulations aim to maintain high standards for clinical practices and safeguard public health.Major Regulatory Bodies Worldwide
1. U.S. Food and Drug Administration (FDA): In the United States, the FDA is a pivotal regulatory authority overseeing the approval and monitoring of pharmaceuticals, medical devices, and biologics. The FDA sets stringent standards for product safety and efficacy, which significantly impacts market entry and ongoing compliance for healthcare companies.2. European Medicines Agency (EMA): The EMA plays a crucial role in the European Union, evaluating and supervising medicinal products. It provides centralized approval for drugs and ensures that products meet rigorous safety and efficacy standards across member states.
3. Health Canada: This agency regulates pharmaceuticals and medical devices in Canada, ensuring that products are safe, effective, and of high quality. Health Canada's regulations are aligned with international standards but tailored to meet national health needs.
4. World Health Organization (WHO): While not a regulatory body in the traditional sense, the WHO sets international health standards and provides guidelines that influence national regulatory frameworks. It plays a key role in global health policy and emergency response.
5. National Medical Products Administration (NMPA): In China, the NMPA regulates the approval and supervision of drugs and medical devices, with an increasing focus on aligning with global standards and facilitating market access.
Request for Customization
Get Customization
SWOT Analysis in the Healthcare Industry
SWOT analysis in the healthcare industry involves a structured assessment of Strengths, Weaknesses, Opportunities, and Threats to identify strategic advantages and areas for improvement.• Strengths: Evaluates internal factors such as advanced technology, skilled personnel, and strong brand reputation. For example, a hospital with cutting-edge medical equipment and specialized staff is considered to have a strong competitive edge.
• Weaknesses: Identifies internal limitations like outdated facilities, regulatory compliance issues, or high operational costs. Weaknesses could include inefficient processes or lack of innovation.
• Opportunities: Assesses external factors that could drive growth, such as emerging medical technologies, expanding markets, or favorable government policies. Opportunities might involve partnerships or new service lines.
• Threats: Examines external challenges such as increasing competition, changing regulations, or economic downturns. Threats might include new entrants with disruptive technologies or stricter regulatory requirements.
Market Segmentation
Segmentation by Type
- AI-powered Diagnostics
- AI-driven Therapeutics
- AI Clinical Decision Support
- AI Imaging
Artificial Intelligence (AI) in Oncology Market Segmentation by Type
www.htfmarketinsights.com
Segmentation by Application
- Cancer Detection
- Treatment Optimization
- Drug Development
- Patient Prognostics
- Clinical Trials
Artificial Intelligence (AI) in Oncology Market Segmentation by Application
www.htfmarketinsights.com
Regional Outlook
The North America currently holds a significant share of the market, primarily due to several key factors: increasing consumption rates, a burgeoning population, and robust economic momentum. These elements collectively drive demand, positioning this region as a leader in the market. On the other hand, Asia-Pacific is rapidly emerging as the fastest-growing area within the industry. This remarkable growth can be attributed to swift infrastructure development, the expansion of various industrial sectors, and a marked increase in consumer demand. These dynamics make this region a crucial player in shaping future market growth. In our report, we cover a comprehensive analysis of the regions and countries, includingRegions
- North America
- LATAM
- West Europe
- Central & Eastern Europe
- Northern Europe
- Southern Europe
- East Asia
- Southeast Asia
- South Asia
- Central Asia
- Oceania
- MEA
Fastest Growing Region
Asia-Pacific
Dominating Region
North America
The company consistently allocates significant resources to expand its research capabilities, develop new medical technologies, and enhance its pharmaceutical portfolio. Johnson & Johnson's investments in R&D, coupled with strategic acquisitions and partnerships, reinforce its position as a major contributor to advancements in healthcare. This focus on innovation and market expansion underscores the critical importance of the North American region in the global healthcare landscape.
- IBM Watson Health (US)
- Tempus Labs (US)
- Paige (US)
- Freenome (US)
- Guardant Health (US)
- DeepMind (UK)
- PathAI (US)
- Butterfly Network (US)
- Google Health (US)
- Roche (Switzerland)
- Siemens Healthineers (Germany)
- GE Healthcare (US)
- Philips Healthcare (Netherlands)
- AstraZeneca (UK)
Artificial Intelligence (AI) in Oncology Market Segmentation by Players
www.htfmarketinsights.com
Regional Analysis
- North America dominates oncology AI adoption due to strong healthcare infrastructure; Europe follows with growing investments; Asia-Pacific early adopter with rising cancer burden and digital health initiatives.
Market Entropy
- In January 2025 saw launches by OncoAI and DeepCure offering AI-powered imaging analysis and predictive models for cancer diagnosis and treatment monitoring. These tools improved early detection rates and personalized therapy adjustments. Adoption grew in Europe and North America with increasing hospital digitization and investment in AI healthcare solutions.
Regulatory Landscape
- Regulations require strict validation of AI algorithms for diagnosis, prognosis, and treatment planning. Data security and patient consent are critical, alongside clinical efficacy evidence.
Patent Analysis
- Surge in patents related to AI algorithms for cancer detection and prognosis; top applicants include tech-health startups and established pharma companies focusing on AI-assisted drug development.
Investment and Funding Scenario
- Venture capital and strategic funding surge for AI in oncology, with $1.2B raised globally in 2024; funding targets AI imaging platforms, molecular diagnostics, and personalized treatment algorithms; cross-border investments increase.
Primary and Secondary Research
Primary research involves the collection of original data directly from sources in the healthcare industry. Approaches include the survey of health professionals, interviews with patients, focus groups, and clinical trials. This gives an overview of the current practice, the needs of the patient, and the interest in emerging trends. Firsthand information on the efficacy of new treatments, an assessment of market demand, and insight into changes in regulation can be sought only with primary research.Secondary Research: This is the investigation of existing information from a variety of sources, which may include industry reports, academic journals, government publications, and market research studies. Alfred secondary research empowers them to understand trends within industries, historical data, and competitive landscapes. It gives a wide view of the market dynamics and validates findings obtained from primary research. By combining both primary and secondary together, health organizations will be empowered to develop comprehensive strategies and make informed decisions based on a strong foundation built on data.
Report Infographics
|
Report Features |
Details |
|
Base Year |
2024 |
|
Based Year Market Size (2023) |
1.1Billion |
|
Historical Period |
2020 to 2024 |
|
CAGR (2024 to 2032) |
26.50% |
|
Forecast Period |
2024 to 2032 |
|
Forecasted Period Market Size (2032) |
4.7Billion |
|
Scope of the Report |
Segmentation by Type AI-powered Diagnostics,AI-driven Therapeutics,AI Clinical Decision Support,AI Imaging, Segmentation by Application Cancer Detection,Treatment Optimization,Drug Development,Patient Prognostics,Clinical Trials, Sales Channel |
|
Regions Covered |
North America, LATAM, West Europe,Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA |
|
Companies Covered |
IBM Watson Health (US),Tempus Labs (US),Paige (US),Freenome (US),Guardant Health (US),DeepMind (UK),PathAI (US),Butterfly Network (US),Google Health (US),Roche (Switzerland),Siemens Healthineers (Germany),GE Healthcare (US),Philips Healthcare (Netherlands),AstraZeneca (UK) |
|
Customization Scope |
15% Free Customization (For EG) |
|
Delivery Format |
PDF and Excel through Email |
Artificial Intelligence (AI) in Oncology - Table of Contents
Chapter 1: Market Preface
- 1.1 Global Artificial Intelligence (AI) in Oncology Market Landscape
- 1.2 Scope of the Study
- 1.3 Relevant Findings & Stakeholder Advantages
Chapter 2: Strategic Overview
- 2.1 Global Artificial Intelligence (AI) in Oncology Market Outlook
- 2.2 Total Addressable Market versus Serviceable Market
- 2.3 Market Rivalry Projection
Chapter 3 : Global Artificial Intelligence (AI) in Oncology Market Business Environment & Changing Dynamics
-
3.1 Growth Drivers
- 3.1.1 Rising cancer cases
- 3.1.2 Precision medicine demand
- 3.1.3 AI tech improvements
- 3.1.4 Healthcare digitization
-
3.2 Available Opportunities
- 3.2.1 Oncology clinical decision support
- 3.2.2 AI-powered drug pipelines
- 3.2.3 Perso
-
3.3 Influencing Trends
- 3.3.1 AI-assisted imaging
- 3.3.2 Predictive oncology models
- 3.3.3 AI drug discovery
- 3.3.4 P
-
3.4 Challenges
- 3.4.1 Regulatory complexity
- 3.4.2 Data security
- 3.4.3 AI transparency
- 3.4.4 Adoption barri
- 3.5 Regional Dynamics
Need only Qualitative Analysis? Get Prices
Sectional Purchase
Chapter 4 : Global Artificial Intelligence (AI) in Oncology Industry Factors Assessment
- 4.1 Current Scenario
- 4.2 PEST Analysis
- 4.3 Business Environment - PORTER 5-Forces Analysis
- 4.3.1 Supplier Leverage
- 4.3.2 Bargaining Power of Buyers
- 4.3.3 Threat of Substitutes
- 4.3.4 Threat from New Entrant
- 4.3.5 Market Competition Level
- 4.4 Roadmap of Artificial Intelligence (AI) in Oncology Market
- 4.5 Impact of Macro-Economic Factors
- 4.6 Market Entry Strategies
- 4.7 Political and Regulatory Landscape
- 4.8 Supply Chain Analysis
- 4.9 Impact of Tariff War
Chapter 5: Artificial Intelligence (AI) in Oncology : Competition Benchmarking & Performance Evaluation
- 5.1 Global Artificial Intelligence (AI) in Oncology Market Concentration Ratio
- 5.1.1 CR4, CR8 and HH Index
- 5.1.2 % Market Share - Top 3
- 5.1.3 Market Holding by Top 5
- 5.2 Market Position of Manufacturers by Artificial Intelligence (AI) in Oncology Revenue 2024
- 5.3 Global Artificial Intelligence (AI) in Oncology Sales Volume by Manufacturers (2024)
- 5.4 BCG Matrix
- 5.4 Market Entropy
- 5.5 5C’s Analysis
- 5.6 Ansoff Matrix
Chapter 6: Global Artificial Intelligence (AI) in Oncology Market: Company Profiles
- 6.1 IBM Watson Health (US)
- 6.1.1 IBM Watson Health (US) Company Overview
- 6.1.2 IBM Watson Health (US) Product/Service Portfolio & Specifications
- 6.1.3 IBM Watson Health (US) Key Financial Metrics
- 6.1.4 IBM Watson Health (US) SWOT Analysis
- 6.1.5 IBM Watson Health (US) Development Activities
- 6.2 Tempus Labs (US)
- 6.3 Paige (US)
- 6.4 Freenome (US)
- 6.5 Guardant Health (US)
- 6.6 DeepMind (UK)
- 6.7 PathAI (US)
- 6.8 Butterfly Network (US)
- 6.9 Google Health (US)
- 6.10 Roche (Switzerland)
- 6.11 Siemens Healthineers (Germany)
- 6.12 GE Healthcare (US)
- 6.13 Philips Healthcare (Netherlands)
- 6.14 AstraZeneca (UK)
- 6.15 Merck (US)
To View a Complete List of Players? Inquiry Now
Sectional Purchase
Chapter 7 : Global Artificial Intelligence (AI) in Oncology by Type & Application (2020-2032)
-
7.1 Global Artificial Intelligence (AI) in Oncology Market Revenue Analysis (USD Million) by Type (2020-2024)
- 7.1.1 AI-powered Diagnostics
- 7.1.2 AI-driven Therapeutics
- 7.1.3 AI Clinical Decision Support
- 7.1.4 AI Imaging
- 7.1.5 AI Genomics
-
7.2 Global Artificial Intelligence (AI) in Oncology Market Revenue Analysis (USD Million) by Application (2020-2024)
- 7.2.1 Cancer Detection
- 7.2.2 Treatment Optimization
- 7.2.3 Drug Development
- 7.2.4 Patient Prognostics
- 7.2.5 Clinical Trials
- 7.3 Global Artificial Intelligence (AI) in Oncology Market Revenue Analysis (USD Million) by Type (2024-2032)
- 7.4 Global Artificial Intelligence (AI) in Oncology Market Revenue Analysis (USD Million) by Application (2024-2032)
Chapter 8 : North America Artificial Intelligence (AI) in Oncology Market Breakdown by Country, Type & Application
- 8.1 North America Artificial Intelligence (AI) in Oncology Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 8.1.1 United States
- 8.1.2 Canada
-
8.2 North America Artificial Intelligence (AI) in Oncology Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 8.2.1 AI-powered Diagnostics
- 8.2.2 AI-driven Therapeutics
- 8.2.3 AI Clinical Decision Support
- 8.2.4 AI Imaging
- 8.2.5 AI Genomics
-
8.3 North America Artificial Intelligence (AI) in Oncology Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 8.3.1 Cancer Detection
- 8.3.2 Treatment Optimization
- 8.3.3 Drug Development
- 8.3.4 Patient Prognostics
- 8.3.5 Clinical Trials
- 8.4 North America Artificial Intelligence (AI) in Oncology Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 8.5 North America Artificial Intelligence (AI) in Oncology Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 8.6 North America Artificial Intelligence (AI) in Oncology Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Looking for Section Purchase? Get Quote Now
Sectional Purchase
Chapter 9 : LATAM Artificial Intelligence (AI) in Oncology Market Breakdown by Country, Type & Application
- 9.1 LATAM Artificial Intelligence (AI) in Oncology Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 9.1.1 Brazil
- 9.1.2 Argentina
- 9.1.3 Chile
- 9.1.4 Mexico
- 9.1.5 Rest of LATAM
-
9.2 LATAM Artificial Intelligence (AI) in Oncology Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 9.2.1 AI-powered Diagnostics
- 9.2.2 AI-driven Therapeutics
- 9.2.3 AI Clinical Decision Support
- 9.2.4 AI Imaging
- 9.2.5 AI Genomics
-
9.3 LATAM Artificial Intelligence (AI) in Oncology Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 9.3.1 Cancer Detection
- 9.3.2 Treatment Optimization
- 9.3.3 Drug Development
- 9.3.4 Patient Prognostics
- 9.3.5 Clinical Trials
- 9.4 LATAM Artificial Intelligence (AI) in Oncology Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 9.5 LATAM Artificial Intelligence (AI) in Oncology Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 9.6 LATAM Artificial Intelligence (AI) in Oncology Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 10 : West Europe Artificial Intelligence (AI) in Oncology Market Breakdown by Country, Type & Application
- 10.1 West Europe Artificial Intelligence (AI) in Oncology Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 10.1.1 Germany
- 10.1.2 France
- 10.1.3 Benelux
- 10.1.4 Switzerland
- 10.1.5 Rest of West Europe
-
10.2 West Europe Artificial Intelligence (AI) in Oncology Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 10.2.1 AI-powered Diagnostics
- 10.2.2 AI-driven Therapeutics
- 10.2.3 AI Clinical Decision Support
- 10.2.4 AI Imaging
- 10.2.5 AI Genomics
-
10.3 West Europe Artificial Intelligence (AI) in Oncology Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 10.3.1 Cancer Detection
- 10.3.2 Treatment Optimization
- 10.3.3 Drug Development
- 10.3.4 Patient Prognostics
- 10.3.5 Clinical Trials
- 10.4 West Europe Artificial Intelligence (AI) in Oncology Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 10.5 West Europe Artificial Intelligence (AI) in Oncology Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 10.6 West Europe Artificial Intelligence (AI) in Oncology Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 11 : Central & Eastern Europe Artificial Intelligence (AI) in Oncology Market Breakdown by Country, Type & Application
- 11.1 Central & Eastern Europe Artificial Intelligence (AI) in Oncology Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 11.1.1 Bulgaria
- 11.1.2 Poland
- 11.1.3 Hungary
- 11.1.4 Romania
- 11.1.5 Rest of CEE
-
11.2 Central & Eastern Europe Artificial Intelligence (AI) in Oncology Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 11.2.1 AI-powered Diagnostics
- 11.2.2 AI-driven Therapeutics
- 11.2.3 AI Clinical Decision Support
- 11.2.4 AI Imaging
- 11.2.5 AI Genomics
-
11.3 Central & Eastern Europe Artificial Intelligence (AI) in Oncology Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 11.3.1 Cancer Detection
- 11.3.2 Treatment Optimization
- 11.3.3 Drug Development
- 11.3.4 Patient Prognostics
- 11.3.5 Clinical Trials
- 11.4 Central & Eastern Europe Artificial Intelligence (AI) in Oncology Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 11.5 Central & Eastern Europe Artificial Intelligence (AI) in Oncology Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 11.6 Central & Eastern Europe Artificial Intelligence (AI) in Oncology Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 12 : Northern Europe Artificial Intelligence (AI) in Oncology Market Breakdown by Country, Type & Application
- 12.1 Northern Europe Artificial Intelligence (AI) in Oncology Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 12.1.1 The United Kingdom
- 12.1.2 Sweden
- 12.1.3 Norway
- 12.1.4 Baltics
- 12.1.5 Ireland
- 12.1.6 Rest of Northern Europe
-
12.2 Northern Europe Artificial Intelligence (AI) in Oncology Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 12.2.1 AI-powered Diagnostics
- 12.2.2 AI-driven Therapeutics
- 12.2.3 AI Clinical Decision Support
- 12.2.4 AI Imaging
- 12.2.5 AI Genomics
-
12.3 Northern Europe Artificial Intelligence (AI) in Oncology Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 12.3.1 Cancer Detection
- 12.3.2 Treatment Optimization
- 12.3.3 Drug Development
- 12.3.4 Patient Prognostics
- 12.3.5 Clinical Trials
- 12.4 Northern Europe Artificial Intelligence (AI) in Oncology Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 12.5 Northern Europe Artificial Intelligence (AI) in Oncology Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 12.6 Northern Europe Artificial Intelligence (AI) in Oncology Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 13 : Southern Europe Artificial Intelligence (AI) in Oncology Market Breakdown by Country, Type & Application
- 13.1 Southern Europe Artificial Intelligence (AI) in Oncology Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 13.1.1 Spain
- 13.1.2 Italy
- 13.1.3 Portugal
- 13.1.4 Greece
- 13.1.5 Rest of Southern Europe
-
13.2 Southern Europe Artificial Intelligence (AI) in Oncology Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 13.2.1 AI-powered Diagnostics
- 13.2.2 AI-driven Therapeutics
- 13.2.3 AI Clinical Decision Support
- 13.2.4 AI Imaging
- 13.2.5 AI Genomics
-
13.3 Southern Europe Artificial Intelligence (AI) in Oncology Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 13.3.1 Cancer Detection
- 13.3.2 Treatment Optimization
- 13.3.3 Drug Development
- 13.3.4 Patient Prognostics
- 13.3.5 Clinical Trials
- 13.4 Southern Europe Artificial Intelligence (AI) in Oncology Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 13.5 Southern Europe Artificial Intelligence (AI) in Oncology Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 13.6 Southern Europe Artificial Intelligence (AI) in Oncology Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 14 : East Asia Artificial Intelligence (AI) in Oncology Market Breakdown by Country, Type & Application
- 14.1 East Asia Artificial Intelligence (AI) in Oncology Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 14.1.1 China
- 14.1.2 Japan
- 14.1.3 South Korea
- 14.1.4 Taiwan
- 14.1.5 Others
-
14.2 East Asia Artificial Intelligence (AI) in Oncology Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 14.2.1 AI-powered Diagnostics
- 14.2.2 AI-driven Therapeutics
- 14.2.3 AI Clinical Decision Support
- 14.2.4 AI Imaging
- 14.2.5 AI Genomics
-
14.3 East Asia Artificial Intelligence (AI) in Oncology Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 14.3.1 Cancer Detection
- 14.3.2 Treatment Optimization
- 14.3.3 Drug Development
- 14.3.4 Patient Prognostics
- 14.3.5 Clinical Trials
- 14.4 East Asia Artificial Intelligence (AI) in Oncology Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 14.5 East Asia Artificial Intelligence (AI) in Oncology Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 14.6 East Asia Artificial Intelligence (AI) in Oncology Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 15 : Southeast Asia Artificial Intelligence (AI) in Oncology Market Breakdown by Country, Type & Application
- 15.1 Southeast Asia Artificial Intelligence (AI) in Oncology Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 15.1.1 Vietnam
- 15.1.2 Singapore
- 15.1.3 Thailand
- 15.1.4 Malaysia
- 15.1.5 Indonesia
- 15.1.6 Philippines
- 15.1.7 Rest of SEA Countries
-
15.2 Southeast Asia Artificial Intelligence (AI) in Oncology Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 15.2.1 AI-powered Diagnostics
- 15.2.2 AI-driven Therapeutics
- 15.2.3 AI Clinical Decision Support
- 15.2.4 AI Imaging
- 15.2.5 AI Genomics
-
15.3 Southeast Asia Artificial Intelligence (AI) in Oncology Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 15.3.1 Cancer Detection
- 15.3.2 Treatment Optimization
- 15.3.3 Drug Development
- 15.3.4 Patient Prognostics
- 15.3.5 Clinical Trials
- 15.4 Southeast Asia Artificial Intelligence (AI) in Oncology Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 15.5 Southeast Asia Artificial Intelligence (AI) in Oncology Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 15.6 Southeast Asia Artificial Intelligence (AI) in Oncology Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 16 : South Asia Artificial Intelligence (AI) in Oncology Market Breakdown by Country, Type & Application
- 16.1 South Asia Artificial Intelligence (AI) in Oncology Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 16.1.1 India
- 16.1.2 Bangladesh
- 16.1.3 Others
-
16.2 South Asia Artificial Intelligence (AI) in Oncology Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 16.2.1 AI-powered Diagnostics
- 16.2.2 AI-driven Therapeutics
- 16.2.3 AI Clinical Decision Support
- 16.2.4 AI Imaging
- 16.2.5 AI Genomics
-
16.3 South Asia Artificial Intelligence (AI) in Oncology Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 16.3.1 Cancer Detection
- 16.3.2 Treatment Optimization
- 16.3.3 Drug Development
- 16.3.4 Patient Prognostics
- 16.3.5 Clinical Trials
- 16.4 South Asia Artificial Intelligence (AI) in Oncology Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 16.5 South Asia Artificial Intelligence (AI) in Oncology Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 16.6 South Asia Artificial Intelligence (AI) in Oncology Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 17 : Central Asia Artificial Intelligence (AI) in Oncology Market Breakdown by Country, Type & Application
- 17.1 Central Asia Artificial Intelligence (AI) in Oncology Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 17.1.1 Kazakhstan
- 17.1.2 Tajikistan
- 17.1.3 Others
-
17.2 Central Asia Artificial Intelligence (AI) in Oncology Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 17.2.1 AI-powered Diagnostics
- 17.2.2 AI-driven Therapeutics
- 17.2.3 AI Clinical Decision Support
- 17.2.4 AI Imaging
- 17.2.5 AI Genomics
-
17.3 Central Asia Artificial Intelligence (AI) in Oncology Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 17.3.1 Cancer Detection
- 17.3.2 Treatment Optimization
- 17.3.3 Drug Development
- 17.3.4 Patient Prognostics
- 17.3.5 Clinical Trials
- 17.4 Central Asia Artificial Intelligence (AI) in Oncology Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 17.5 Central Asia Artificial Intelligence (AI) in Oncology Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 17.6 Central Asia Artificial Intelligence (AI) in Oncology Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 18 : Oceania Artificial Intelligence (AI) in Oncology Market Breakdown by Country, Type & Application
- 18.1 Oceania Artificial Intelligence (AI) in Oncology Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 18.1.1 Australia
- 18.1.2 New Zealand
- 18.1.3 Others
-
18.2 Oceania Artificial Intelligence (AI) in Oncology Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 18.2.1 AI-powered Diagnostics
- 18.2.2 AI-driven Therapeutics
- 18.2.3 AI Clinical Decision Support
- 18.2.4 AI Imaging
- 18.2.5 AI Genomics
-
18.3 Oceania Artificial Intelligence (AI) in Oncology Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 18.3.1 Cancer Detection
- 18.3.2 Treatment Optimization
- 18.3.3 Drug Development
- 18.3.4 Patient Prognostics
- 18.3.5 Clinical Trials
- 18.4 Oceania Artificial Intelligence (AI) in Oncology Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 18.5 Oceania Artificial Intelligence (AI) in Oncology Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 18.6 Oceania Artificial Intelligence (AI) in Oncology Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 19 : MEA Artificial Intelligence (AI) in Oncology Market Breakdown by Country, Type & Application
- 19.1 MEA Artificial Intelligence (AI) in Oncology Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 19.1.1 Turkey
- 19.1.2 South Africa
- 19.1.3 Egypt
- 19.1.4 UAE
- 19.1.5 Saudi Arabia
- 19.1.6 Israel
- 19.1.7 Rest of MEA
-
19.2 MEA Artificial Intelligence (AI) in Oncology Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 19.2.1 AI-powered Diagnostics
- 19.2.2 AI-driven Therapeutics
- 19.2.3 AI Clinical Decision Support
- 19.2.4 AI Imaging
- 19.2.5 AI Genomics
-
19.3 MEA Artificial Intelligence (AI) in Oncology Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 19.3.1 Cancer Detection
- 19.3.2 Treatment Optimization
- 19.3.3 Drug Development
- 19.3.4 Patient Prognostics
- 19.3.5 Clinical Trials
- 19.4 MEA Artificial Intelligence (AI) in Oncology Market by Country (USD Million) & Sales Volume (Units) [2025-2032]
- 19.5 MEA Artificial Intelligence (AI) in Oncology Market by Type (USD Million) & Sales Volume (Units) [2025-2032]
- 19.6 MEA Artificial Intelligence (AI) in Oncology Market by Application (USD Million) & Sales Volume (Units) [2025-2032]
Chapter 20: Research Findings & Conclusion
- 20.1 Key Findings
- 20.2 Conclusion
Chapter 21: Methodology and Data Source
-
21.1 Research Methodology & Approach
- 21.1.1 Research Program/Design
- 21.1.2 Market Size Estimation
- 21.1.3 Market Breakdown and Data Triangulation
-
21.2 Data Source
- 21.2.1 Secondary Sources
- 21.2.2 Primary Sources
Chapter 22: Appendix & Disclaimer
- 22.1 Acronyms & bibliography
- 22.2 Disclaimer
Frequently Asked Questions (FAQ):
The Artificial Intelligence (AI) in Oncology Market is growing at a steady pace over the last few years and is expected to grow at a CAGR of 26.50% from 2024 to 2032 to reach a market size of 26.50% 4.7 Billion
The Artificial Intelligence (AI) in Oncology Market is predicted to grow at a CAGR of 26.50%.
The changing dynamics and trends such as AI-assisted Imaging,Predictive Oncology Models,AI Drug Discovery,Patient Monitoring Platforms,Digital Biomarkers are seen as major Game Changer in Global Artificial Intelligence (AI) in Oncology Market.
The leaders in the Global Artificial Intelligence (AI) in Oncology Market such as IBM Watson Health (US),Tempus Labs (US),Paige (US),Freenome (US),Guardant Health (US),DeepMind (UK),PathAI (US),Butterfly Network (US),Google Health (US),Roche (Switzerland),Siemens Healthineers (Germany),GE Healthcare (US),Philips Healthcare (Netherlands),AstraZeneca (UK),Merck (US) are targeting innovative and differentiated growth drivers some of them are Rising Cancer Cases,Precision Medicine Demand,AI Tech Improvements,Healthcare Digitization,Research Funding
Some of the major roadblocks that industry players have identified are Regulatory Complexity,Data Security,AI Transparency,Adoption Barriers,Clinical Validation.
Some of the opportunities that Analyst at HTF MI have identified in Artificial Intelligence (AI) in Oncology Market are:
- Oncology Clinical Decision Support
- AI-powered Drug Pipelines
- Personalized Therapies
- Early Detection Tools
- Market Growth
New entrants, including competitors from unrelated industries along with players such as IBM Watson Health (US),Tempus Labs (US),Paige (US),Freenome (US),Guardant Health (US),DeepMind (UK),PathAI (US),Butterfly Network (US),Google Health (US),Roche (Switzerland),Siemens Healthineers (Germany),GE Healthcare (US),Philips Healthcare (Netherlands),AstraZeneca (UK),Merck (US) Instituting a robust process in Global Artificial Intelligence (AI) in Oncology Market.
The Global Artificial Intelligence (AI) in Oncology Market Study is Broken down by applications such as Cancer Detection,Treatment Optimization,Drug Development,Patient Prognostics,Clinical Trials.
The Global Artificial Intelligence (AI) in Oncology Market Study is segmented by AI-powered Diagnostics,AI-driven Therapeutics,AI Clinical Decision Support,AI Imaging,AI Genomics.
The Global Artificial Intelligence (AI) in Oncology Market Study includes regional breakdown as North America, LATAM, West Europe,Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA
The Artificial Intelligence (AI) in Oncology Market is studied from 2020 - 2032.
AI in Oncology utilizes artificial intelligence technologies to improve cancer diagnosis, treatment planning, and patient management. AI algorithms analyze medical images, genomic data, and clinical records to detect cancer early and recommend personalized therapies. It supports clinicians in making informed decisions and advancing precision oncology. This technology accelerates drug discovery and clinical trial design for better cancer outcomes.
